At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...

Cancer research saves lives and leads to improved outcomes for patients. But federal cancer research funding may be in jeopardy for 2026.

Emerging treatments like rusfertide may reduce phlebotomies and improve life for patients with polycythemia vera, according ...

OptimTM accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 27 ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

Asco has shared plans for his new album 'Perfect Timing'. The UK rapper is known as one of the best in his lane, with Asco's expert pen game inspiring his ...

Introducing the Bi/Multispecific Drugs in Oncology Analytical Tool – revolutionizing cancer care with precision, immune activation, and therapeutic potential. In 2024/25, 278 new drugs highlighted ...

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

Saipem, the Italian oilfield services giant, has successfully completed the installation of an approximately 80-kilometer ...